Integration of PEG 400 into a self-nanoemulsifying drug delivery system improves drug loading capacity and nasal mucosa permeability and prolongs the survival of rats with malignant brain tumors

Yu-Shuan Chen,1–3 Yu-Han Chiu,3 Yuan-Sheng Li,3 En-Yi Lin,3,4 Dean-Kuo Hsieh,5 Chia-Hung Lee,3 Mao-Hsuan Huang,1 Hong-Meng Chuang,1 Shinn-Zong Lin,1,6 Horng-Jyh Harn,1,7,* Tzyy-Wen Chiou3,*1Bioinnovation Center, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan, Republic of China; 2Depa...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Chen YS, Chiu YH, Li YS, Lin EY, Hsieh DK, Lee CH, Huang MH, Chuang HM, Lin SZ, Harn HJ, Chiou TW
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2019
Materias:
Acceso en línea:https://doaj.org/article/f5cc0768e0d7468bb39c6fa07455b290
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:f5cc0768e0d7468bb39c6fa07455b290
record_format dspace
spelling oai:doaj.org-article:f5cc0768e0d7468bb39c6fa07455b2902021-12-02T05:40:28ZIntegration of PEG 400 into a self-nanoemulsifying drug delivery system improves drug loading capacity and nasal mucosa permeability and prolongs the survival of rats with malignant brain tumors1178-2013https://doaj.org/article/f5cc0768e0d7468bb39c6fa07455b2902019-05-01T00:00:00Zhttps://www.dovepress.com/integration-of-peg-400-into-a-self-nanoemulsifying-drug-delivery-syste-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Yu-Shuan Chen,1–3 Yu-Han Chiu,3 Yuan-Sheng Li,3 En-Yi Lin,3,4 Dean-Kuo Hsieh,5 Chia-Hung Lee,3 Mao-Hsuan Huang,1 Hong-Meng Chuang,1 Shinn-Zong Lin,1,6 Horng-Jyh Harn,1,7,* Tzyy-Wen Chiou3,*1Bioinnovation Center, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan, Republic of China; 2Department of Medical Research, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan, Republic of China; 3Department of Life Science and Graduate Institute of Biotechnology, National Dong Hwa University, Hualien, Taiwan, Republic of China; 4Department of Chemistry, National Dong Hwa University, Hualien, Taiwan, Republic of China; 5Department and Graduate Institute of Applied Chemistry, Chaoyang University of Technology, Taichung, Taiwan, Republic of China; 6Department of Neurosurgery, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan, Republic of China; 7Department of Pathology, Hualien Tzu Chi Hospital, Tzu Chi University, Hualien, Taiwan, Republic of China*These authors contributed equally to this workIntroduction: Kolliphor® EL (K-EL) is among the most useful surfactants in the preparation of emulsions. However, it is associated with low hydrophobic drug loading in the resulting emulsified formulation.Methods: In this study, a formulation for intranasal administration of butylidenephthalide (Bdph), a candidate drug against glioblastoma (GBM), was prepared. Physical characteristics of the formulation such as particle size, zeta potential, conductivity, and viscosity were assessed, as well as its cytotoxicity and permeability, in order to optimize the formulation and improve its drug loading capacity.Results: The optimized formulation involved the integration of polyethylene glycol 400 (PEG 400) in K-EL to encapsulate Bdph dissolved in dimethyl sulfoxide (DMSO), and it exhibited higher drug loading capacity and drug solubility in water than the old formulation, which did not contain PEG 400. Incorporation of PEG 400 as a co-surfactant increased Bdph loading capacity to up to 50% (v/v), even in formulations using Kolliphor® HS 15 (K-HS15) as a surfactant, which is less compatible with Bdph than K-EL. The optimized Bdph formulation presented 5- and 2.5-fold higher permeability and cytotoxicity, respectively, in human GBM than stock Bdph. This could be attributed to the high drug loading capacity and the high polarity index due to DMSO, which increases the compatibility between the drug and the cell. Rats bearing a brain glioma treated with 160 mg/kg intranasal emulsified Bdph had a mean survival of 37 days, which is the same survival time achieved by treatment with 320 mg/kg stock Bdph. This implies that the optimized emulsified formulation required only half the Bdph dose to achieve an efficacy similar to that of stock Bdph in the treatment of animals with malignant brain tumor.Keywords: glioblastoma, polyethylene glycol 400, butylidenephthalide, loading capacity, permeability, intranasal administrationChen YSChiu YHLi YSLin EYHsieh DKLee CHHuang MHChuang HMLin SZHarn HJChiou TWDove Medical PressarticleGlioblastomaPolyethylene glycol 400butylidenephthalideloading capacitypermeabilityintranasal administrationMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 14, Pp 3601-3613 (2019)
institution DOAJ
collection DOAJ
language EN
topic Glioblastoma
Polyethylene glycol 400
butylidenephthalide
loading capacity
permeability
intranasal administration
Medicine (General)
R5-920
spellingShingle Glioblastoma
Polyethylene glycol 400
butylidenephthalide
loading capacity
permeability
intranasal administration
Medicine (General)
R5-920
Chen YS
Chiu YH
Li YS
Lin EY
Hsieh DK
Lee CH
Huang MH
Chuang HM
Lin SZ
Harn HJ
Chiou TW
Integration of PEG 400 into a self-nanoemulsifying drug delivery system improves drug loading capacity and nasal mucosa permeability and prolongs the survival of rats with malignant brain tumors
description Yu-Shuan Chen,1–3 Yu-Han Chiu,3 Yuan-Sheng Li,3 En-Yi Lin,3,4 Dean-Kuo Hsieh,5 Chia-Hung Lee,3 Mao-Hsuan Huang,1 Hong-Meng Chuang,1 Shinn-Zong Lin,1,6 Horng-Jyh Harn,1,7,* Tzyy-Wen Chiou3,*1Bioinnovation Center, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan, Republic of China; 2Department of Medical Research, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan, Republic of China; 3Department of Life Science and Graduate Institute of Biotechnology, National Dong Hwa University, Hualien, Taiwan, Republic of China; 4Department of Chemistry, National Dong Hwa University, Hualien, Taiwan, Republic of China; 5Department and Graduate Institute of Applied Chemistry, Chaoyang University of Technology, Taichung, Taiwan, Republic of China; 6Department of Neurosurgery, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan, Republic of China; 7Department of Pathology, Hualien Tzu Chi Hospital, Tzu Chi University, Hualien, Taiwan, Republic of China*These authors contributed equally to this workIntroduction: Kolliphor® EL (K-EL) is among the most useful surfactants in the preparation of emulsions. However, it is associated with low hydrophobic drug loading in the resulting emulsified formulation.Methods: In this study, a formulation for intranasal administration of butylidenephthalide (Bdph), a candidate drug against glioblastoma (GBM), was prepared. Physical characteristics of the formulation such as particle size, zeta potential, conductivity, and viscosity were assessed, as well as its cytotoxicity and permeability, in order to optimize the formulation and improve its drug loading capacity.Results: The optimized formulation involved the integration of polyethylene glycol 400 (PEG 400) in K-EL to encapsulate Bdph dissolved in dimethyl sulfoxide (DMSO), and it exhibited higher drug loading capacity and drug solubility in water than the old formulation, which did not contain PEG 400. Incorporation of PEG 400 as a co-surfactant increased Bdph loading capacity to up to 50% (v/v), even in formulations using Kolliphor® HS 15 (K-HS15) as a surfactant, which is less compatible with Bdph than K-EL. The optimized Bdph formulation presented 5- and 2.5-fold higher permeability and cytotoxicity, respectively, in human GBM than stock Bdph. This could be attributed to the high drug loading capacity and the high polarity index due to DMSO, which increases the compatibility between the drug and the cell. Rats bearing a brain glioma treated with 160 mg/kg intranasal emulsified Bdph had a mean survival of 37 days, which is the same survival time achieved by treatment with 320 mg/kg stock Bdph. This implies that the optimized emulsified formulation required only half the Bdph dose to achieve an efficacy similar to that of stock Bdph in the treatment of animals with malignant brain tumor.Keywords: glioblastoma, polyethylene glycol 400, butylidenephthalide, loading capacity, permeability, intranasal administration
format article
author Chen YS
Chiu YH
Li YS
Lin EY
Hsieh DK
Lee CH
Huang MH
Chuang HM
Lin SZ
Harn HJ
Chiou TW
author_facet Chen YS
Chiu YH
Li YS
Lin EY
Hsieh DK
Lee CH
Huang MH
Chuang HM
Lin SZ
Harn HJ
Chiou TW
author_sort Chen YS
title Integration of PEG 400 into a self-nanoemulsifying drug delivery system improves drug loading capacity and nasal mucosa permeability and prolongs the survival of rats with malignant brain tumors
title_short Integration of PEG 400 into a self-nanoemulsifying drug delivery system improves drug loading capacity and nasal mucosa permeability and prolongs the survival of rats with malignant brain tumors
title_full Integration of PEG 400 into a self-nanoemulsifying drug delivery system improves drug loading capacity and nasal mucosa permeability and prolongs the survival of rats with malignant brain tumors
title_fullStr Integration of PEG 400 into a self-nanoemulsifying drug delivery system improves drug loading capacity and nasal mucosa permeability and prolongs the survival of rats with malignant brain tumors
title_full_unstemmed Integration of PEG 400 into a self-nanoemulsifying drug delivery system improves drug loading capacity and nasal mucosa permeability and prolongs the survival of rats with malignant brain tumors
title_sort integration of peg 400 into a self-nanoemulsifying drug delivery system improves drug loading capacity and nasal mucosa permeability and prolongs the survival of rats with malignant brain tumors
publisher Dove Medical Press
publishDate 2019
url https://doaj.org/article/f5cc0768e0d7468bb39c6fa07455b290
work_keys_str_mv AT chenys integrationofpeg400intoaselfnanoemulsifyingdrugdeliverysystemimprovesdrugloadingcapacityandnasalmucosapermeabilityandprolongsthesurvivalofratswithmalignantbraintumors
AT chiuyh integrationofpeg400intoaselfnanoemulsifyingdrugdeliverysystemimprovesdrugloadingcapacityandnasalmucosapermeabilityandprolongsthesurvivalofratswithmalignantbraintumors
AT liys integrationofpeg400intoaselfnanoemulsifyingdrugdeliverysystemimprovesdrugloadingcapacityandnasalmucosapermeabilityandprolongsthesurvivalofratswithmalignantbraintumors
AT liney integrationofpeg400intoaselfnanoemulsifyingdrugdeliverysystemimprovesdrugloadingcapacityandnasalmucosapermeabilityandprolongsthesurvivalofratswithmalignantbraintumors
AT hsiehdk integrationofpeg400intoaselfnanoemulsifyingdrugdeliverysystemimprovesdrugloadingcapacityandnasalmucosapermeabilityandprolongsthesurvivalofratswithmalignantbraintumors
AT leech integrationofpeg400intoaselfnanoemulsifyingdrugdeliverysystemimprovesdrugloadingcapacityandnasalmucosapermeabilityandprolongsthesurvivalofratswithmalignantbraintumors
AT huangmh integrationofpeg400intoaselfnanoemulsifyingdrugdeliverysystemimprovesdrugloadingcapacityandnasalmucosapermeabilityandprolongsthesurvivalofratswithmalignantbraintumors
AT chuanghm integrationofpeg400intoaselfnanoemulsifyingdrugdeliverysystemimprovesdrugloadingcapacityandnasalmucosapermeabilityandprolongsthesurvivalofratswithmalignantbraintumors
AT linsz integrationofpeg400intoaselfnanoemulsifyingdrugdeliverysystemimprovesdrugloadingcapacityandnasalmucosapermeabilityandprolongsthesurvivalofratswithmalignantbraintumors
AT harnhj integrationofpeg400intoaselfnanoemulsifyingdrugdeliverysystemimprovesdrugloadingcapacityandnasalmucosapermeabilityandprolongsthesurvivalofratswithmalignantbraintumors
AT chioutw integrationofpeg400intoaselfnanoemulsifyingdrugdeliverysystemimprovesdrugloadingcapacityandnasalmucosapermeabilityandprolongsthesurvivalofratswithmalignantbraintumors
_version_ 1718400329707421696